Jazz Pharmaceuticals has rebuffed attempts by rival Teva Pharmaceuticals to legally disqualify its patent for Epidyolex, a cannabis-based drug worth
Northern Leaf Jersey-based medical cannabis cultivator Northern Leaf is reportedly aiming to raise a further £3m in pre-IPO funding with
WITH the fast-growing CBD sector tied up in a regulatory quagmire hundreds of transatlantic industry players face an uncertain future. However, one
PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals (“GW”;
Jazz Pharmaceuticals Jazz Pharmaceuticals, which has become the world’s largest exporter of medical cannabis products since it bought GW Pharmaceuticals
JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals (“GW”) – a world leader in discovering, developing and delivering
Argent BioPharma Argent BioPharma has managed to overcome the wider chaos on the stock markets this week, seeing its
Earlier this week, Jazz dismissed a patent claim against Apotex, Canada’s largest generic drug producer, as it reached a settlement with the company, the details of which were undisclosed.
British American Tobacco Tobacco giant British American Tobacco (BAT) has announced the launch of a second investment fund as
Jazz Pharmaceuticals The pharmaceutical giant announced last week that its flagship cannabinoid treatment, Epidyolex, failed to pass its Phase
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
